LUCEMYRA Drug Patent Profile
✉ Email this page to a colleague
When do Lucemyra patents expire, and what generic alternatives are available?
Lucemyra is a drug marketed by Uswm and is included in one NDA.
The generic ingredient in LUCEMYRA is lofexidine hydrochloride. Four suppliers are listed for this compound. Additional details are available on the lofexidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lucemyra
A generic version of LUCEMYRA was approved as lofexidine hydrochloride by INDOCO on August 20th, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LUCEMYRA?
- What are the global sales for LUCEMYRA?
- What is Average Wholesale Price for LUCEMYRA?
Summary for LUCEMYRA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 68 |
| Clinical Trials: | 9 |
| Patent Applications: | 183 |
| Drug Prices: | Drug price information for LUCEMYRA |
| What excipients (inactive ingredients) are in LUCEMYRA? | LUCEMYRA excipients list |
| DailyMed Link: | LUCEMYRA at DailyMed |
Recent Clinical Trials for LUCEMYRA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute on Drug Abuse (NIDA) | Phase 1/Phase 2 |
| New York State Psychiatric Institute | Phase 1/Phase 2 |
| Clinilabs, Inc. | Phase 1/Phase 2 |
US Patents and Regulatory Information for LUCEMYRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Uswm | LUCEMYRA | lofexidine hydrochloride | TABLET;ORAL | 209229-001 | May 16, 2018 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
